Form 4: Ocular Therapeutix Chief Medical Officer Nadia Waheed Reports Stock and Option Grants

Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Summary

• Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, filed a Form 4 on June 4, 2024, reporting transactions that occurred on June 1, 2024.
• Waheed was granted 141,666 restricted stock units (RSUs) under the 2019 Inducement Stock Incentive Plan, each representing one share of Ocular Therapeutix common stock.
• These RSUs will vest in equal annual installments over three years, starting on the grant date, contingent upon continued service to the Corporation.
• Waheed also acquired options to purchase 425,000 shares of common stock at an exercise price of $5.70.
• These options vest over four years, with 25% vesting on the one-year anniversary of employment and the remaining 2.0833% vesting monthly thereafter.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes management. There are no indications of financial distress or negative events.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Industry Context

Stock option and RSU grants are common practice in the biotech industry to incentivize key executives and align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in publicly traded biotech companies typically include a mix of stock options and restricted stock units.
• The size of the grant is generally determined by the company's market capitalization, the executive's experience, and industry benchmarks.
• Vesting schedules are also standard, usually ranging from three to four years, to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the fact that key executives are incentivized to improve company performance.

Key Dates